Lakefront Biotherapeutics Says FDA Granted Orphan Drug Designation To Gamgertamig For Treatment Of Pemphigus
Share
Why It Matters
The FDA said Lakefront's new medicine for a rare skin disease gets special status, which means the company might get extra help and time to develop it. This shows the FDA thinks the medicine could be worth making, which is a green light that investors watch for.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.